培菲康联合奥沙拉嗪治疗溃疡性结肠炎疗效观察

目的观察培菲康联合奥沙拉嗪治疗溃疡性结肠炎的临床疗效。方法肠镜确诊43例轻、中度溃疡性结肠炎患者随机分为治疗组(22例)和对照组(21例)。治疗组给予培菲康420 mg,口服,3次/d;奥沙拉嗪1.0,口服,4次/d。对照组予奥沙拉嗪1.0,口服,4次/d;疗程均为8周。治疗后,进行症状评分,复查肠镜取病理观察组织学变化。结果显效率、总有效率治疗组分别为40.9%和90.9%,对照组分别为28.6%和76.2%,经χ2检验差异均有显著意义(P<0.05)。结论培菲康联合奥沙拉嗪治疗溃疡性结肠炎的疗效优于单用奥沙拉嗪。

Clinical Effect of Bifico Combined Olsalazine in Treating Ulcerative Colitis

Objective To Observe the clinical efficacy of bifico combined Olsalazine in the treatment of ulcerative colitis. Methods 43 cases of mild to moderate ulcerative colitis who diagnosed by Colonoscopy were randomly divided into treatment group （22 cases） and control group （21 cases）. Treatment group was given bifico 420mg, orally, three times a day, olsalazine 1.0, orally, four times a day; The control group were given Olsalazine 1.0, orally, four times a day; treatment were 8 weeks. Symptom score were recorded after treatment. We reviewed colonoscopy and and raked patholog- ical histological changes. Results Excellence rate, the total effective rate were 40.9 % and 90.9%. In control group was 28.6% and 76.2% （ P 〈 0.05）. Conclusion Bifico combined olsalazine treatment of ulcerative colitis is better than alone olsalazine.